Eye (London, England) · 2026
Early detection of neovascular age-related macular degeneration in the second eye reduces intravitreal treatment burden: FASBAT report 2.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hanson Rachel L W, Airody Archana, Sivaprasad Sobha, McKibbin Martin, Morland Antony B, Peto Tunde, Chakravarthy Usha, Gale Richard P, FASBAT study group
Аннотация
BACKGROUND/OBJECTIVES: To investigate if early detection of neovascular age-related macular degeneration (nAMD) in the second eye is associated with a reduced number of intravitreal treatments compared with the first eye using data from the EDNA/FASBAT trial.
SUBJECTS/METHODS: Post-hoc analysis of 117 participants receiving standard clinical care during the FASBAT study. Assessments were at enrolment and at an average of 18.9 (SD = 10.2) and 30.5 (SD = 9.7) months in the first eye. Assessment of the second eye was made at the onset of nAMD (as participants were monitored for conversion) and at 12- and 24-months. The annualised injection rate for first eyes and the actual rate for second eyes are reported alongside visual acuity (VA) and optical coherence tomography (OCT) characteristics.
RESULTS: In second eyes the annualised number of treatments was lower both in year 1 (second eyes mean = 6.4, SD = 3.4 vs mean = 7.2, SD = 1.9 in first eyes) and in year 2 (second eyes mean = 5.8, SD = 2.9; versus mean = 6.2, SD = 2.7 in first eyes). Second eyes had better VA at the point of conversion to nAMD (mean = 74.1, SD = 9.9) compared with the first eyes at baseline (mean = 55.6, SD = 15.3) which was maintained until 24 months (second eye: mean = 73.6, SD = 9.9; first eye: mean = 53.2, SD = 19.3). Highly reflective material was detected less frequently in second eyes compared to first eyes at clinical visits.
CONCLUSIONS: Compared to first eyes, early detection of nAMD in the second eye is beneficial in terms of better maintenance of visual acuity, reduced intravitreal treatment burden, and improved anatomical findings after 2 years of treatment.
SUBJECTS/METHODS: Post-hoc analysis of 117 participants receiving standard clinical care during the FASBAT study. Assessments were at enrolment and at an average of 18.9 (SD = 10.2) and 30.5 (SD = 9.7) months in the first eye. Assessment of the second eye was made at the onset of nAMD (as participants were monitored for conversion) and at 12- and 24-months. The annualised injection rate for first eyes and the actual rate for second eyes are reported alongside visual acuity (VA) and optical coherence tomography (OCT) characteristics.
RESULTS: In second eyes the annualised number of treatments was lower both in year 1 (second eyes mean = 6.4, SD = 3.4 vs mean = 7.2, SD = 1.9 in first eyes) and in year 2 (second eyes mean = 5.8, SD = 2.9; versus mean = 6.2, SD = 2.7 in first eyes). Second eyes had better VA at the point of conversion to nAMD (mean = 74.1, SD = 9.9) compared with the first eyes at baseline (mean = 55.6, SD = 15.3) which was maintained until 24 months (second eye: mean = 73.6, SD = 9.9; first eye: mean = 53.2, SD = 19.3). Highly reflective material was detected less frequently in second eyes compared to first eyes at clinical visits.
CONCLUSIONS: Compared to first eyes, early detection of nAMD in the second eye is beneficial in terms of better maintenance of visual acuity, reduced intravitreal treatment burden, and improved anatomical findings after 2 years of treatment.